Jasper Therapeutics, Inc. (Nasdaq: JSPR) announced the termination of its offer to purchase outstanding warrants on November 9, 2026. The offer expired at 12:00 a.m., Eastern Time, on November 7, 2026, and was made pursuant to an Offer to Purchase filed with the SEC on October 7, 2026.
According to the company, a total of 8,510,658 warrants were properly tendered and not withdrawn. This represents approximately 68.94% of the outstanding warrants. The warrants were originally issued and sold as part of an underwritten public offering on September 18, 2025.
Pursuant to the terms of the offer, Jasper Therapeutics expects to pay an aggregate of $2,757,453.19 in cash to warrant holders. The company stated that such payment will be made promptly.
Jasper Therapeutics is a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases. The company is advancing a pipeline of medicines including vensobafusp alfa, briquilimab, and KP701.
